PION Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA521092-Each-of-1 | In Stock | ₹ 49,439.50 |
PIPA521092 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 49,439.50
GST (18%): ₹ 8,899.11
Total Price: ₹ 58,338.61
Antigen
PION
Classification
Polyclonal
Conjugate
Unconjugated
Gene
GSAP
Gene Alias
A530088I07Rik; gamma-secretase activating protein; gamma-secretase-activating protein; Gamma-secretase-activating protein 16 kDa C-terminal form; GSAP; GSAP-16K; pigeon homolog; Pion; Protein pigeon homolog; tcag7.1314
Host Species
Rabbit
Purification Method
Antigen affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
212167, 311984, 54103
Content And Storage
Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C
Form
Liquid
Applications
Immunohistochemistry, Western Blot
Concentration
1 mg/mL
Formulation
PBS with 0.02% sodium azide
Gene Accession No.
A4D1B5, Q3TCV3
Gene Symbols
GSAP
Immunogen
A 19 amino acid peptide near the carboxy terminus of human PION.
Quantity
100 μg
Primary or Secondary
Primary
Target Species
Human, Mouse, Rat
Product Type
Antibody
Isotype
IgG
Related Products
Description
- A suggested positive control is EL4 cell lysate
- PA5-21092 can be used with blocking peptide PEP-1206
- Accumulation of the amyloid-beta peptide (Abeta) in the cerebral cortex is a critical event in the pathogenesis of Alzheimer’s disease
- The beta-amyloid protein precursor (APP) is cleaved by one of two beta-secretases (BACE and BACE2), producing a soluble derivative of the protein and a membrane anchored 99 -amino acid carboxy-terminal fragment (C99)
- The C99 fragment serves as substrate for -gamma-secretase to generate the 4 kDa amyloid-beta peptide (Abeta), which is deposited in the Alzheimer’s disease patients’ brains
- PION, or GSAP, selectively increases amyloid-beta production through a mechanism involving its interaction with both -gamma-secretase and the APP C-terminal fragment, suggesting that PION may be a potential therapeutic target for the treatment of Alzheimer’s disease.